Prime Medicine (PRME) Current Leases (2021 - 2026)

Prime Medicine (PRME) has 6 years of Current Leases data on file, last reported at $8.5 million in Q1 2026.

• Quarterly Current Leases rose 24.61% year-over-year to $8.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.5 million (up 24.61% YoY) and the FY2025 annual result came in at $8.1 million, up 125.15% from the prior year.
• Current Leases advanced to $8.5 million in Q1 2026, from $8.1 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $13.5 million in Q2 2023 to a low of $3.6 million in Q4 2024.
• A 5-year average of $8.5 million and a median of $8.1 million in 2025 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2024 — Current Leases tumbled 61.39% — and 2025, when it jumped 125.15%.
• Tracing PRME's Current Leases over 5 years: stood at $11.7 million in 2022, then dropped by 20.68% to $9.3 million in 2023, then slumped by 61.04% to $3.6 million in 2024, then jumped by 125.15% to $8.1 million in 2025, then grew by 5.03% to $8.5 million in 2026.
• The last three Current Leases figures came in at $8.5 million (Q1 2026), $8.1 million (Q4 2025), and $7.7 million (Q3 2025), per Business Quant data.